Keeping Track: US FDA Clears Sanofi’s Sarclisa; KemPharm Submits Novel ADHD Drug
The latest drug development news and highlights from the Pink Sheet FDA Performance Tracker.
You may also be interested in...
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.
A dozen applications for new drugs and significant new indications are on the US FDA’s calendar of goal dates, including breakthrough-designated applications from Bristol-Myers Squibb and Boehringer Ingelheim.
Keeping Track Of User Fee Decisions And Filings: Adakveo, Brukinsa And Fetroja Mark Massive Week Of Novel Approvals
The latest news on US FDA user fee decisions and submissions to the agency.